Lesson
Diagnose Disease and Measure the Whole Burden
Atopic dermatitis is a relapsing pruritic inflammatory disease diagnosed clinically. Morphology, age-patterned distribution, xerosis, chronicity, burden, and competing diagnoses matter together.
- Pruritic eczema
- Age distribution
- Validated severity
- Mimics
- Urgent infection
Use age, site, morphology, xerosis, and history
Measure itch, sleep, pain, infection, function, and mood
Consider contact disease, scabies, psoriasis, infection, and drug eruption
Escalate infection and systemic threat
Build the clinical pattern
Ask when itch began, where rash appears, how it changes, and whether xerosis, flexural disease, facial or hand involvement, lichenification, family atopy, asthma, or rhinitis supports the pattern. Skin color changes how erythema appears.
Measure more than surface area
Use a consistent clinician measure such as EASI or a validated global assessment when available, plus body surface area, itch, sleep, pain, infections, school or work, mood, and treatment burden. Hands, face, eyelids, and genitals can cause major disability with limited area.
Protect the differential
Allergic or irritant contact dermatitis, scabies, psoriasis, seborrheic dermatitis, dermatophyte infection, drug eruption, immunodeficiency, cutaneous lymphoma, and other disorders can mimic eczema. Unusual age, morphology, distribution, systemic findings, or treatment failure requires reassessment.
Escalate dangerous change
Fever, severe pain, rapidly spreading redness, purulence, eye symptoms, or clusters of painful vesicles and punched-out erosions can indicate serious bacterial infection or eczema herpeticum. These findings need prompt direct evaluation.
Quick check
Lesson
Connect Barrier Failure, Immunity, and Itch
Barrier proteins and lipids, type 2 inflammation, microbial interaction, neural itch, and scratching form a self-reinforcing circuit. Treatment must interrupt several links.
- Barrier lipids
- IL-4 and IL-13
- IL-31
- JAK signaling
- Itch scratch cycle
Dryness and fissures increase irritant entry
Inflammation and itch weaken the barrier
Excoriation deepens inflammation and infection risk
Treat both sides of the circuit
Start with the barrier
Impaired proteins and lipids increase transepidermal water loss and allow irritants, allergens, and microbes to interact with the immune system. Moisturizer supports barrier function but does not replace anti-inflammatory treatment during active disease.
Map type 2 signaling
IL-4 and IL-13 contribute to inflammation and further barrier dysfunction. IL-31 is strongly linked to itch, while intracellular JAK pathways transmit several cytokine signals. These pathways explain targeted therapies without reducing the disease to one molecule.
Break the itch scratch circuit
Scratching injures skin, intensifies inflammation, increases infection risk, and disrupts sleep. Control skin inflammation, protect nails and sleep, reduce friction, and use behavioral and physical strategies.
Do not confuse sedation with disease control
Oral antihistamines do not routinely treat the core inflammation or itch of atopic dermatitis. A short sedating strategy may occasionally address severe sleep disruption under clinician direction, but it adds cognitive, anticholinergic, respiratory, and fall risks.
Quick check
Lesson
Engineer Daily Barrier Care and Trigger Reasoning
Bathing, moisturizer, cleanser, climate, sensory preference, work, and reproducible exposures shape the barrier. Broad avoidance and unvalidated food restriction can create harm.
- Bathing
- Moisturizer vehicle
- Fragrance and cleanser
- Contact allergy
- Food restriction
Avoid prolonged hot exposure
Choose a tolerated ointment, cream, or lotion
Reduce cleanser and product burden
Use patch testing when contact allergy is plausible
Add water, then retain it
Use brief comfortable bathing and a gentle cleanser only where needed. Pat rather than rub and apply a generous fragrance-free moisturizer promptly while skin is still slightly damp. Frequency and vehicle should match the patient and climate.
Select a usable vehicle
Ointments are highly occlusive, creams balance occlusion and feel, and lotions are lighter but often less occlusive and may contain more water or preservatives. The best product is bland, affordable, tolerated, and used consistently.
Find irritants and contact allergy
Review fragrance, preservatives, soaps, metals, adhesives, gloves, wet work, hair and cosmetic products, occupation, heat, sweat, friction, and clothing. Patch testing can identify allergic contact dermatitis when site, exposure, or treatment resistance supports it.
Avoid unsupported restriction
Food allergy can coexist, especially in children, but broad panels and elimination diets do not diagnose the cause of eczema. Restriction without a convincing immediate history and specialist evaluation can impair nutrition, growth, and quality of life.
Quick check
Lesson
Use Topical Corticosteroids with Measured Precision
Topical corticosteroids remain foundational. Potency, vehicle, site, age, amount, frequency, duration, occlusion, and total steroid exposure determine benefit and harm.
- Potency classes
- Fingertip units
- Sensitive sites
- Wet wraps
- Cumulative toxicity
Skin vulnerability and thickness differ
Write grams, frequency, duration, and stop rules
Avoid undertreatment driven by vague fear
Watch atrophy, striae, eye, infection, growth, and HPA risk
Match potency to anatomy and flare
Thick hand, foot, or lichenified disease may require greater potency than face, eyelid, fold, or genital skin. Children and large-area disease increase absorption. Vehicle changes delivery and acceptability.
Make the dose measurable
Fingertip units and body maps help estimate amount. Write which product goes where, how often, for how many days, and what replaces it after control. Tube size and refill timing reveal undertreatment or excessive exposure.
Counsel without amplifying phobia
Explain that adequate short-course treatment prevents prolonged inflammation, while unsupervised high-potency or continuous sensitive-site use can cause atrophy, striae, telangiectasia, acneiform change, periorificial dermatitis, ocular harm, and systemic absorption.
Treat occlusion as a dose multiplier
Wet wraps can rapidly improve selected flares, but hydration and occlusion increase drug delivery. Use clinician-directed potency, dilution when applicable, area, duration, temperature, infection screening, and caregiver technique.
Quick check
Lesson
Use Established Steroid-Sparing Topicals
Topical calcineurin inhibitors and crisaborole reduce inflammation without corticosteroid atrophy. Their distinct mechanisms, labels, sensations, and maintenance roles guide use.
- Tacrolimus
- Pimecrolimus
- Crisaborole
- Application burning
- Proactive therapy
Calcineurin inhibitors avoid steroid atrophy
Set expectations and protect adherence
Follow exact twice-daily labeling
Treat recurrent sites between flares
Use calcineurin inhibitors on vulnerable sites
Tacrolimus ointment and pimecrolimus cream are useful on the face, eyelids, folds, and other sites where corticosteroid atrophy is concerning. Current product age, strength, infection, sun, and boxed-warning counseling remain specific.
Discuss the warning accurately
Transient burning or stinging is common, especially on inflamed skin. Explain the label warning and available evidence in context, avoid use on active infection, and use sun protection rather than allowing fear or dismissal to replace shared decision-making.
Place crisaborole precisely
Crisaborole 2 percent ointment is labeled twice daily for mild to moderate disease from age 3 months. Application-site pain or burning can limit use, and rare hypersensitivity requires discontinuation and evaluation.
Maintain recurrent sites proactively
After a flare is controlled, clinician-directed intermittent topical anti-inflammatory therapy at repeat sites plus daily moisturizer can delay relapse. Track rescue days and product amounts rather than waiting for severe recurrence.
Quick check
Lesson
Navigate the Current Nonsteroidal Topical Landscape
The 2025 AAD focused update strongly recommends tapinarof and roflumilast for adult disease, while current labels add pediatric, strength, area, and exposure details. June 2026 labeling expands topical ruxolitinib to age two.
- Tapinarof
- Roflumilast
- Ruxolitinib
- Age-specific strengths
- Body surface limits
Once daily from age 2
Age-specific 0.05 and 0.15 percent strengths
Short-term, noncontinuous, up to 20 percent body area
Topical route still requires exposure controls
Use tapinarof by indication
Tapinarof cream 1 percent is an aryl hydrocarbon receptor agonist labeled once daily for atopic dermatitis in adults and children age 2 and older. Monitor folliculitis, contact dermatitis, headache, and other current-label adverse reactions.
Use the correct roflumilast strength
Roflumilast is a PDE4 inhibitor. Current labeling uses cream 0.15 percent once daily from age 6 and cream 0.05 percent once daily from age 2 through 5 for mild to moderate atopic dermatitis. Moderate to severe liver impairment is a contraindication.
Respect topical ruxolitinib limits
Current June 2026 labeling covers non-immunocompromised patients age 2 and older with mild to moderate disease not adequately controlled by other topical prescriptions. Apply twice daily to no more than 20 percent body surface area, avoid occlusion, respect age-specific tube limits, and stop when signs resolve.
Keep boxed safety visible
Ruxolitinib labeling carries JAK-class serious infection, mortality, malignancy, major cardiovascular event, thrombosis, and cytopenia warnings. Combination with therapeutic biologics, other JAK inhibitors, azathioprine, or cyclosporine is not recommended.
Quick check
Lesson
Separate Flare Rescue from Infection Treatment
Inflamed eczema is not automatically infected. Bacterial infection, eczema herpeticum, fungal disease, and irritant reactions require different actions, while wraps and bleach baths require exact technique.
- Impetiginization
- Eczema herpeticum
- Antimicrobial stewardship
- Wet wraps
- Bleach baths
Identify bacterial, viral, fungal, or systemic threat
Avoid routine antimicrobials for every flare
Occlusion changes absorption and infection risk
Exact volume, concentration, frequency, and supervision
Find clinical infection
Pain, purulence, pustules, rapidly spreading erythema, fever, systemic illness, or worsening despite adequate anti-inflammatory care supports bacterial evaluation. Culture severe, recurrent, unusual, or treatment-resistant disease when results will change care.
Protect the herpes pathway
Painful monomorphic vesicles, punched-out erosions, fever, malaise, or eye-area involvement raises concern for eczema herpeticum. Arrange prompt antiviral and ophthalmic evaluation when relevant rather than waiting for routine flare treatment.
Avoid routine antimicrobials
AAD guidance recommends against routine topical antimicrobials and antiseptics for uninfected dermatitis. Oral antibiotics are reserved for evidence of bacterial infection and are combined with adequate eczema therapy.
Measure physical adjuncts
Wet wraps require product and duration supervision. Dilute bleach baths may help selected recurrent infection-prone disease, but household product concentration, tub volume, dose, frequency, ventilation, rinse, and moisturization must be exact.
Quick check
Lesson
Select Phototherapy and Biologics by Pathway and Product
Current systemic guidance strongly supports dupilumab, tralokinumab, lebrikizumab, and nemolizumab for appropriate disease. Target, age, weight, topical companion use, eye risk, vaccination, and schedule differ.
- Narrowband UVB
- Dupilumab
- Tralokinumab
- Lebrikizumab
- Nemolizumab
Broad type 2 pathway with product-specific age and weight dosing
Distinct labels, schedules, and eye monitoring
Itch pathway with concomitant topical therapy
Dosed medical exposure, not tanning
Use phototherapy as measured medicine
Narrowband UVB can treat selected widespread disease when topical care is inadequate and attendance is feasible. Review skin cancer, photodermatosis, photosensitizing medicines, burns, pigment response, eye protection, pregnancy, and cumulative exposure. Tanning beds are not equivalent.
Differentiate type 2 biologics
Dupilumab blocks IL-4 receptor alpha signaling, while tralokinumab and lebrikizumab target IL-13. Loading dose, age, weight, interval, conjunctivitis and keratitis surveillance, herpes and helminth context, vaccination, and approved use differ.
Place lebrikizumab accurately
Current labeling covers adults and adolescents age 12 and older who weigh at least 40 kilograms with moderate to severe disease not adequately controlled by topical prescriptions or when those therapies are not advisable.
Place nemolizumab accurately
Nemolizumab blocks IL-31 receptor alpha and is labeled with topical corticosteroids and or calcineurin inhibitors for selected moderate to severe disease from age 12. Weight affects loading, and patients who reach clear or almost clear skin at week 16 can move to the label-directed longer interval.
Quick check
Lesson
Use Systemic Therapy with a Durable Safety Strategy
Oral JAK inhibitors offer rapid targeted therapy for selected patients, conventional immunosuppressants remain conditional options, and routine systemic corticosteroids are discouraged because rescue without durability can rebound.
- Abrocitinib
- Upadacitinib
- Cyclosporine
- Methotrexate
- Systemic corticosteroids
Screen infection, thrombosis, cardiovascular, cancer, and laboratory risk
Cyclosporine, methotrexate, azathioprine, or mycophenolate
Rebound and cumulative harm undermine durable care
Every rescue needs a long-term plan
Screen oral JAK candidates
Abrocitinib and upadacitinib require current-label assessment of serious infection, tuberculosis, viral hepatitis, malignancy, major cardiovascular events, thrombosis, blood counts, liver, lipids, vaccination, pregnancy, smoking, age, and CYP interactions.
Use conventional agents deliberately
Cyclosporine, methotrexate, azathioprine, and mycophenolate remain conditional specialist options. Kidney, pressure, liver, marrow, pregnancy, infection, cancer, pharmacogenetic testing when relevant, and drug interactions vary by agent.
Avoid routine systemic corticosteroids
AAD guidelines recommend against systemic corticosteroids for routine atopic dermatitis management. Short-lived improvement can be followed by rebound, while repeated exposure adds infection, metabolic, bone, eye, mood, adrenal, and cardiovascular harm.
Design the transition before rescue
Every systemic plan needs response targets, timing, laboratory and symptom monitoring, vaccination and infection instructions, pregnancy planning, access continuity, taper or stop criteria, and a maintenance or next-line strategy.
Quick check
Lesson
Close the Loop Across Age, Skin, and Life
Children, pregnancy, darker skin, hands and face, atopic comorbidity, infection, sleep, mental health, access, and caregiver technique can change both disease recognition and treatment success.
- Pediatrics
- Pregnancy
- Skin color
- Atopic comorbidity
- Response targets
Treat neonatal and poorly examinable disease differently
Balance indication, evidence, and drainage reduction
Define a response window for every plan
Escalate whenever the pattern threatens vision
Use exact pediatric assessment and labeling
Do not stop after wax if impairment remains
Define a 48 to 72 hour checkpoint when infection is treated
Act on mastoid, neurologic, invasive, or sudden findings
Use age-specific labels and quantities
Reconcile every topical and systemic exposure
Do not rely on redness alone
Set targets, timing, and escalation
Individualize exposure
Name the actual systemic product
Confirm safe execution
Define the next decision
Prevent formulation errors
Use product-specific evidence
Hypersensitivity resolves slowly
Separate activity from recovery
Use pediatric labels and quantities
Age, weight, body surface area, thin skin, growth, caregiver skill, school, sleep, and accidental exposure matter. Demonstrate quantities and keep medicines secured. Unusual infection, failure to thrive, or very early severe disease broadens the differential.
Use narrative reproductive reasoning
Replace old pregnancy letters with product-specific human and animal evidence, maternal disease burden, route, exposure area, timing, alternatives, lactation, and shared goals. Review every topical, systemic, OTC, and natural product.
Recognize inflammation across skin tones
Erythema may appear violaceous, gray, dark brown, or subtle. Texture, warmth, edema, excoriation, lichenification, pigment change, symptoms, and patient comparison help prevent underestimation.
Measure meaningful response
Track extent and intensity with itch, sleep, pain, infection, hand and face function, mood, school or work, treatment time, product amount, and patient goals. Escalate when adequate technique and exposure do not meet targets.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 112 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.